Advertisement

Topics

BIOCAD: The first ever biosimilar of interferon beta-1a approved in Russia

05:21 EST 3 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
The Ministry of Health (MoH) of the Russian Federation has awarded Biocad marketing authorization for its interferon beta-1a biosimilar, a knockoff of Biogen’s Rebif® that is a key component in treatment of relapsing-remittin...

Other Sources for this Article

BIOCAD
Irina Kenyukhova
Tel: +7 (812) 3804933, ext. 632
E-Mail: kenyukhova@biocad.ru

NEXT ARTICLE

More From BioPortfolio on "BIOCAD: The first ever biosimilar of interferon beta-1a approved in Russia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...